Editors' ChoiceCancer

Doubling down on tumor suppressor deletion

See allHide authors and affiliations

Science Translational Medicine  01 Jan 2020:
Vol. 12, Issue 524, eaba2903
DOI: 10.1126/scitranslmed.aba2903

Abstract

Codeletion of BRCA2 and RB1 increases prostate cancer sensitivity to PARP inhibitor therapy.

View Full Text

Stay Connected to Science Translational Medicine


Editor's Blog